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Vitamin D deﬁciency is common among patients with psychotic disorders and could be due to unknown
disease mechanisms or contingent factors. However most studies are performed in chronic patients and
have often failed to address the inﬂuence of ethnicity on vitamin D levels in clinical samples. We in-
vestigated serum concentrations of 25-hydroxy vitamin D (S-25 OH D) in ﬁrst episode patients compared
to patients with multi episodes and healthy controls; with a speciﬁc focus on differences between visible
ethnic minorities and participants from the majority population. A total of 284 participants were in-
cluded in this cross-sectional study. First episode patients with a DSM-IV psychotic disorder were
matched on age, gender and ethnicity to participants from a multi episode patient sample (1:1) and
healthy controls (1:2). We did not ﬁnd any differences between either patient groups or the healthy
controls, but participants from visible ethnic minorities had signiﬁcantly lower S-25 OH D than parti-
cipants from the majority population. This implies that S-25 OH D should be routinely measured in
persons from visible ethnic minorities since low levels are associated with higher levels of depressive
symptoms.
& 2015 Published by Elsevier Ireland Ltd.1. Introduction
The active metabolite of vitamin D is a steroid hormone with
multiple functions. It binds to the vitamin D receptor (VDR) which
is found in most parts of the body, including the immune system
(Fernandes de Abreu et al., 2009) and the central nervous system
(Stumpf, 2012). Vitamin D is involved in the proliferation, differ-
entiation and growth of neurons and has an important role in
neuroplasticity (Deluca et al., 2013) both in the developing and
adult brain.
Two recent meta-analyses have indicated signiﬁcantly lower
serum–25 hydroxy vitamin D (S-25 OH D) in patients with es-
tablished psychiatric disorders compared to healthy controls
(Belvederi Murri et al., 2013; Valipour et al., 2014), in line with
previous studies showing an association between lower S-25 OH D
and having a diagnosis in the schizophrenia spectrum (Rey-erhus).
al., Vitamin D status in psy
2015), http://dx.doi.org/10.1Sanchez et al., 2009; Partti et al., 2010). Correspondingly, in a study
of diagnostically diverse psychiatric out-patients the lowest S-25
OH D levels were found in patients with schizophrenia or autism
spectrum disorders (Humble et al., 2010). There are thus relatively
consistent indications of lower S-25 OH D in patients with psy-
chotic disorders, especially schizophrenia. To what extent the low
vitamin D levels are related to (hitherto unknown) disease me-
chanisms or secondary to poor nutrition, reduced self-care or
medication use is not known. Most studies have included chronic
patients, i.e. groups that probably will be more inﬂuenced by these
types of contingent factors than patients with a recent onset of
their disease. However only two earlier studies have up to now
been conducted in ﬁrst episode/ﬁrst treatment samples and their
ﬁndings are equivocal. One study (N¼138) found signiﬁcantly
lower S-25 OH D in both white and black patients, but not in pa-
tients of Asian origin, compared to healthy controls (Crews et al.,
2013). The other small study (N¼40) did not ﬁnd any patient/
control differences (Graham et al., 2014).
The main source of vitamin D is ultraviolet B (UVB) radiation
from the sun. Dark skin (high pigmentation), body-coveringchotic disorder patients and healthy controls – The inﬂuence of
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able UVB radiation, dependent on geographical latitude and sea-
son of the year, in affecting vitamin D levels in the body (Wacker
and Holick, 2013). This is of interest for the study of psychotic
disorders since there are consistent ﬁndings of a higher incidence
of psychotic disorders in immigrants and visible ethnic minorities,
in particular dark-skinned immigrants to countries with pre-
dominantly white majority populations, i.e. countries at high la-
titudes (Cantor-Graae and Selten, 2005). There are however few
studies of the associations between ethnic background and vita-
min D levels in psychotic disorders. In the current clinical cross
sectional study we thus aimed to explore differences in S-25 OH D
between a ﬁrst episode psychosis patient sample, compared to a
multi-episode patient sample and a healthy control sample mat-
ched for age, gender and ethnic background. We investigated if:
i. First episode patients and multi-episode patients have lower
S-25 OH D than the healthy controls.
ii. Participants from visible ethnic minorities across the two pa-
tient groups and in the healthy control group have lower S-25
OH D than participants from the majority population.2. Methods
Participants were recruited consecutively between May 2010
and April 2014 from in-and out-patient psychiatric units in the
catchment areas of the four major hospitals in Oslo, as part of the
larger Thematically Organized Psychosis (TOP) Study. The Regional
Committee for Medical Research Ethics approved the study and
our research methodology conformed to The Code of Ethics of the
World Medical Association, Helsinki Declaration. All participants
gave informed written consent to participate.
2.1. Participants
A power analysis based on group differences (means and
standard deviations) from the previous vitamin D in FEP study
(Crews et al., 2013) indicated that a group size of 46 participants
would be sufﬁcient to detect real differences given the expected
differences and standard deviations. A total of 71 ﬁrst episode
patients (FEP) with a DSM-IV psychotic disorder (Schizophrenia
spectrum i.e. schizophrenia, schizophreniform and schizoaffective,
N¼46; other psychosis i.e. delusional disorder, brief psychotic
episode, psychotic depressive disorder and psychosis NOS, N¼25)
were included. Participants were deﬁned as FEP if they gave con-
sent to be recruited into the study within one year after start of
their ﬁrst adequate treatment (deﬁned as admission to hospital or
antipsychotic medication in adequate doses) for a psychotic epi-
sode (deﬁned as at least one week with a score of four or more on
Positive and Negative Syndrome Scale for Schizophrenia on items
P1, P3, P5, P6 or G9). As a proxy for skin pigmentation the parti-
cipants' ethnicity was used to divide the participants into two
groups, one group including participants with European ancestry
(majority population group), and one group with participants of
Asian, Latin-American and African ancestry (visible ethnic minor-
ity group). The FEP sample was then matched 1:1 on visible ethnic
minority status, age, gender and diagnosis to a multi episode
sample (MEP) and then matched 1:2 to healthy controls (HC)
drawn from the same catchment area in the following manner:
Participants from the majority population were directly matched
with HC from the control group of the TOP study. Due to a low
number with visible ethnic minority status in this control group,
participants with visible ethnic minority background (i.e. from
Asia including Turkey (N¼17), Africa (N¼17) and Latin-America
(N¼6)) were matched with HC of visible ethnic minorityPlease cite this article as: Nerhus, M., et al., Vitamin D status in psy
ethnic background. Psychiatry Research (2015), http://dx.doi.org/10.1background (Asia including Turkey) from a population-based
health study including immigrants to the city of Oslo; the Oslo
Immigrant Health Study (2002) (http://www.fhi.no/artikler/?
id¼53584).
2.2. Procedures
2.2.1. Clinical
All patients were assessed by trained clinical research person-
nel. Demographic and clinical variables and the use of medication
were obtained by clinical interviews by protocol and by conferring
the medical records. The Structured Clinical Interview for DSM-IV
Axis I Disorders (SCID-I) was used for diagnostic purposes. In the
FEP group, duration of untreated psychotic illness was measured
in weeks. In the FEP and MEP groups total duration of illness
(including treated and untreated phases) was measured in years
and calculated as age minus age at onset. Current symptomatology
was assessed by The Structured Interview for the Positive and
Negative Syndrome Scale (PANSS) (Kay et al., 1987). At inclusion
the participants went through a physical examination with blood
sample withdrawal. Height and weight were measured by a
standard procedure, and BMI was calculated by kg/m².
2.2.2. Biochemical
In the TOP sample; 25-OH D (25-OH D2 and 25-OH D3) serum
concentrations were determined using a liquid chromatography–
tandem mass spectrometry (LC–MS/MS) method developed at the
Hormone laboratory (Oslo University Hospital, Norway) (Supple-
mentary materials 1). In the Oslo Immigrant Health Study, S-25 OH
D was measured by a radioimmunoassay (RIA kit from Diasorin)
(Holvik et al., 2005). The equation LC-MS/MS¼1.16×(RIA)−9 was
calibrated at the laboratory for comparisons and the calibrated
values from the Oslo Immigrant Health Study are used in the
current study.
2.3. Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics v.
22 (IBM corp. 2014). The level of signiﬁcance was preset to Po0.05
(two tailed). Student t-tests and one way ANOVAs with Tukey post
hoc tests were used for group comparisons of continuous vari-
ables, chi-square tests for categorical variables and Pearson's r for
bivariate correlations. Normally distribution of the continuous
variables was evaluated by normality plots and found to be sa-
tisfactory with the exception of the assessments of duration of
untreated psychosis and total duration of illness where we used
Spearman's correlations. For statistical purposes, season was di-
chotomized into winter (December–May) and summer (June–No-
vember) (Porojnicu et al., 2007). For PANSS we used the ﬁve factor
model by Wallwork et al. (2012). Seven participants had missing
values for BMI; ﬁve had missing values for age at onset, three had
missing values for in-vs out-patient status and nine had missing
values for regular use of antipsychotic medication or not. In the
multivariate analyses missing values were replaced with group
means for independent continuous variables and mode (most used
value) for independent dichotomous variables. To investigate the
potential inﬂuence of confounders, variables that were either
statistically signiﬁcantly associated with S-25 OH D or differed
across groups (i.e. FEP, MEP or HC) or ethnicity (majority popula-
tion or visible ethnic minority) in bivariate analyses were entered
as covariates in an ANCOVA with S-25 OH D as the dependent
variable; here group membership (FEP, MEP or HC) and ethnicity
were ﬁxed factors in the model. The analyses were then repeated
in the subsample containing only patients with a narrow schizo-
phrenia spectrum diagnosis (schizophrenia n¼77, schizophreni-
form n¼8, schizoaffective n¼15). Finally we performed a secondchotic disorder patients and healthy controls – The inﬂuence of
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gender, BMI and ethnicity as covariates to investigate the group by
season interaction.S-25 OH D nmol/L
mean (SD)
First episode psychosis 44.8 (19.5)
Multi episode psychosis 43.1 (20.3)
Healthy controls 45.1 (21.4) F¼0.23df 2,281, P¼0.80
Winter season 40.7 (20.4)
Summer season 50.3 (19.6) t¼3.96df 282, Po0.01
Ethnic minority status 29.5 (16.3)
Majority population 50.4 (19.1) t¼8.65df 282, Po0.01
Men 42.6 (19.8)
Women 48.1 (21.6) t¼2.16df 282, P¼0.033. Results
The demographic and clinical sample characteristics are shown
in Table 1. Due to the matching procedure the age and gender by
ethnicity distribution found in the FEP group were repeated in the
MEP and in HC groups. The following variables differed between
the groups: The MEP sample had signiﬁcantly higher BMI than
both FEP and HC with mean values slightly above upper limit of
the normal range according to the WHO deﬁnition (range 18.5–
24.9). The majority of HC had their blood samples taken during
winter season. Concerning differences between the ethnic groups,
there were a larger proportion of males in the visible minority
group than in the majority group (80% vs 60%, P¼0.001).
There were no signiﬁcant differences in unadjusted S-25 OH D
between the FEP, MEP and HC. S-25 OH D was lower in males, in
samples drawn during the winter season and in visible ethnic
minorities (Table 2). Visible ethnic minorities had signiﬁcantly
higher BMI than participants from the majority population (mean
26.1 vs. 24.6 kg/m2, P¼0.003). There were no signiﬁcant associa-
tions between age, BMI and S-25 OH D in neither patient groups or
in controls. In both patient groups (FEP and MEP) neither age at
onset, tobacco consumption, regular use of psychopharmacologi-
cal medication, being in-versus outpatient, duration of illness nor
duration of untreated psychosis (in the FEP group) were associated
with S-25 OH D (data not shown). S-25 OH D was not signiﬁcantly
correlated with the positive or the negative symptom factor from
the PANSS (r¼0.07, p¼0.57 in FEP; r¼0.03, P¼0.81 in MEPTable 1
Demographic and clinical characteristics of the samples.
First episode Multi episode Healthy controls
FEP MEP HC
N¼71 N¼71 N¼142
N (%) N (%) N (%) Chi²
Schizophrenia spectrum 46 (64.8) 54 (76.1) P¼0.14
Male gender 46 (64.8) 46 (64.8) 92 (64.8) P¼1
Ethnic minority status 20 (28.2) 20 (28.2) 40 (28.2) P¼1
Summer season 31 (43.7) 38 (53.5) 44 (31.0) P¼0.01a
Medicatedb 59 (83.1) 68 (95.8) P¼0.09
AP/LIT/AE/AD/HYPc 55/2/4/17/4 65/6/8/25/5
Hospitalized 31 (43.7) 24 (35.3) P¼0.31
Mean (SD) Mean (SD) ANOVA
Age 27.3 (8.2) 28.0 (8.1) 28.0 (7.6) P¼0.80
Age at onset 24.5 (7.5) 21.7 (7.0) P¼0.03
BMI 25.0 (4.0) 26.8 (4.7) 24.1 (4.0) Po0.01d
Positive symptomse 2.4 (1.0) 2.2 (1.0) P¼0.30
Negative symptomsf 2.1 (0.9) 2.0 (0.9) P¼0.47
Depressive symptomsg 2.4 (0.9) 2.4 (1.1) P¼0.87
Duration of illnessh 2.8 (4.1) 6.3 (6.8) Po0.01i
DUPj 100.5 (22.6)
a Tukey post hoc test MEP4HC
b Regular use of psychopharmacological medication.
c Regular use of antipsychotics/ lithium/ anti epileptics/ anti-depressives/
hypnotics.
d Tukey post hoc test MEP4HC, FEP.
e PANSS score (p1þp3þp5þg9)/4.
f PANSS score (n1þn2þn3þn4þn6þg7)/6.
g PANSS score (g2þg3þg6)/3.
h Duration of illness in years.
i Non parametric Kruskal–Wallis test.
j Duration of untreated psychosis in weeks.
Please cite this article as: Nerhus, M., et al., Vitamin D status in psy
ethnic background. Psychiatry Research (2015), http://dx.doi.org/10.1and r¼0.15, P¼0.20 in FEP; r¼0.04, P¼0.74 in MEP, respec-
tively). There was however a signiﬁcant association between lower
S-25 OH D and higher levels for the depressive symptom factor in
FEP (r¼0.25, p¼0.04), but not in MEP (r¼0.07, P¼0.57). The
ﬁrst ANCOVA shows that the variation in S-25 OH D was mainly
explained by differences in ethnicity and seasonal variation (Ta-
ble 3). There was no effect of group membership (FEP, MEP or HC).
The same results were found when the analyses were repeated,
this time only including patients with a narrow schizophrenia
spectrum diagnosis (data not shown). There was a trend level in-
teraction effect (P¼0.06) between group (FEP, MEP or HC) and
ethnicity; within the majority population there was lower S-25 OH
D levels in MEP than in HC while in visible ethnic minorities theTable 3
ANCOVAwith S- 25 OH D as dependent variable, group (FEP, MEP, HC) and ethnicity
as ﬁxed factors.
95% Conﬁdence
interval
F (df) Signiﬁcance
Meana lower
bound
upper
bound
Gender 0.51 (1,275) 0.48
BMI 0.01 (1,275) 0.91
Season 6.63 (1,275) 0.011
Ethnicity 47.20 (1,275) o0.001
Groupb 0.02 (2,275) 0.98
Group*ethnicity 2.86 (2,275) 0.06
Total
sample
HC 40.2 36.8 43.7
FEP 40.6 35.9 45.3
MEP 39.9 35.0 44.8
Majority population Sigiﬁcancec
HC 53.3 49.4 56.7 FEPvs.HC 1.00
FEP 50.0 44.8 55.1 FEPvs.MEP 0.76
MEP 45.7 40.4 50.9 MEPvs.HC 0.08
Visible ethnic
minorities
HC 25.4 19.4 31.4 FEPvs.HC 0.62
FEP 31.8 24.4 39.2 FEPvs.MEP 1.00
MEP 35.4 26.9 43.9 MEPvs.HC 0.27
a First episode psychosis (FEP), multi episode psychosis (MEP) or healthy con-
trols (HC).
b S-25 OH D nmol/L adjusted for gender, BMI and season.
c Bonferroni adjustment for multiple comparisons.
chotic disorder patients and healthy controls – The inﬂuence of
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in HC. The differences did however not reach the preset level of
statistical signiﬁcance after controlling for BMI (Table 3). The
second ANCOVA shows that there was a group by season inter-
action effect (F¼4.02 (df 2,275), P¼0.02), based in higher varia-
bility across seasons in healthy controls: The highest S-25 OH D
was found in healthy controls in summer season and the lowest in
winter season while S-25 OH D had more stable values across
seasons in the patient groups (FEP and MEP).
In both FEP, MEP and in HC, S-25 OH D was signiﬁcantly lower
in visible ethnic minorities than in the corresponding majority
population (F¼11.85 (df 1,66), P¼0.001 in FEP; F¼4.48 (df 1,66),
P¼0.04 in MEP and F¼39.61 (df 1,137), Po0.001 in HC) (Fig. 1).
There were no statistically signiﬁcant differences in S-25 OH D
levels between different ethnic minorities across groups. Partici-
pants of Latin-American ancestry however had nominally higher
levels than participants with Asian or African ancestry 43.8(29.5),
P¼0.5 versus Asia (31.8(16.0)) and P¼0.6 versus Africa (32.5
(11.9)). Analyses within each clinical group showed that S-25 OH D
was nominally lower in MEP than in HC during summer season in
participants from the majority population (46.8þ20.0 nmol/L vs.
60.3þ17.2 nmol/L), but this difference did not reach the level of
statistical signiﬁcance (P¼0.06).4. Discussion
In the current study we did not ﬁnd any statistically signiﬁcant
differences in vitamin D status between a group of ﬁrst episode
patients, when compared to multi-episode patients and to healthy
controls, respectively. There were however signiﬁcant differences
in S-25 OH D between participants from visible ethnic minorities
and participants from the majority population.
This ﬁrst ﬁnding is in contrast to earlier case-control studies
including patients with established psychotic disorders (Rey-San-
chez et al., 2009; Partti et al., 2010; Itzhaky et al., 2012; Jamilian
et al., 2013). These previous studies however have methodological
limitations, including lack of adjustment for ethnicity (Rey-San-
chez et al., 2009; Partti et al., 2010; Doknic et al., 2011; Jamilian
et al., 2013), comparison between hospitalized patients and health
care workers (Itzhaky et al., 2012) or hospitalized patients and
healthy controls recruited by advertisements without control for
place of residence (Crews et al., 2013). The healthy controls in the
current study were randomly recruited from the same catchment
area as the study patients and matched both for ethnicity and
other important confounding variables such as gender and age. A
review of reported vitamin D levels from these previous studies
actually show remarkably similar vitamin D levels for the patient
groups, but with considerable variations in the levels of the con-
trol groups. Our analyses underline this as we found largerPlease cite this article as: Nerhus, M., et al., Vitamin D status in psy
ethnic background. Psychiatry Research (2015), http://dx.doi.org/10.1seasonal variations in vitamin D levels in healthy controls than in
the patient groups.
The current ﬁndings are also in contrast to a previous study
from our group, that found lower S-25 OH D in a clinical patient
sample compared to a population based control sample, both from
the Norwegian population (Berg et al., 2010). The main difference
between the current study and the previous is that Berg used a
control group where data on vitamin D, age and season for blood
sampling were provided from a population study as means and
standard deviations at group level. The current study has control
samples with individual data for each participant, thus enabling us
to match directly on important background variables including
age. Since psychotic disorders have onset in adolescence or early
adulthood, clinical samples can often be younger than the healthy
controls, and this is of importance since there is a possibility for an
age gradient in S-25 OH D levels. Since older and more chronic
patient groups are more prone to be inﬂuenced by illness related
lifestyle factors it is possible that investigations of this patient
group will show differences between patients and controls in-
dependent of ethnic background.
Visible ethnic minority status was a strong predictor of low
S-25 OH D both in patients and in healthy controls. The crude
observed difference in S-25 OH D between ethnic groups could be
inﬂated, because a large proportion of the HC group for adminis-
trative reasons had their S-25 OH D measured during the winter
season. However, ethnicity still had a strong and statistically sig-
niﬁcant effect on S-25 OH D also after adjustment for season
(Table 3). These ﬁndings are in line with previous research in the
area showing high levels of insufﬁcient S-25 OH D in visible ethnic
minorities in Northern hemisphere (Holvik et al., 2005; Andersen
et al., 2007). People living in Norway have poor access to vitamin D
from the sun, because of high latitude and long winter seasons
(Wacker and Holick, 2013). In the absence of sun exposure through
winter, diet and supplements become all the more important, but
natural sources are few (mainly fatty ﬁsh and cod liver oil). Thus,
cultural differences in diet can be one of the reasons for alarmingly
low S-25 OH D both in patients and healthy controls from visible
ethnic minorities. Possibly, language barriers could also lead to a
failure in reaching the ethnic minority population with advices
regarding use of supplements. The ﬁnding that MEP from the
visible ethnic minority group actually had higher S-25 OH D dur-
ing winter than summer could indicate that health care workers
aware of their heightened risk of vitamin D deﬁciency during the
winter season actively encouraged their use of dietary supple-
ments. Our analyses also showed that the S-25 OH D in healthy
controls from the majority population varied more between win-
ter and summer than in the corresponding patient groups. This
could be explained by contingent factors such as reduced outdoor
activities in the patient group during summer, compared to heal-
thy controls.
This high proportion of patients with low S- 25 OH D is of
importance since this might inﬂuence morbidity both related to
depressive (Berg et al., 2010), positive (Yuksel et al., 2014), nega-
tive (Graham et al., 2014) or atypical symptoms (Dealberto, 2013).
There were no signiﬁcant correlations between S-25 OH D and
positive or negative symptomatology in the current study, but
there was a moderate association between low S-25 OH D and
increased depressive symptomatology in the FEP group. Indica-
tions of an association between low S-25 OH D and depression has
been shown previously, but should be investigated further in a
larger samples because vitamin D substitution could represent a
possible intervention strategy in persons from visible ethnic
minorities. We would however need randomized controlled trials
to evaluate the effect. Another point of importance is that the risk
of cardiovascular diseases and metabolic syndrome has been
found to be associated with psychotic disorders (Johnsen et al.,chotic disorder patients and healthy controls – The inﬂuence of
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related to inadequate S-25 OH D levels (Choi et al., 2014; Menezes
et al., 2014; Ruwanpathirana et al., 2014). Elevated risk of cardio-
vascular disease and metabolic syndrome in psychotic disorder in
visible ethnic minorities has been demonstrated in long-term
follow-ups (Henderson et al., 2005). It is thus of interest that, in
our age and gender matched sample, visible ethnic minorities also
had signiﬁcantly higher BMI than the group recruited from the
majority population, as well as lower S-25 OH D.
While we did not ﬁnd any differences in S-25 OH D between
adult patients with psychotic disorders and healthy controls,
prospective studies have suggested vitamin D deﬁciency as a
contributing factor to higher risk of developing psychotic disorders
in dark skinned immigrants (McGrath, 1999, 2011; Dealberto,
2007; Kinney et al., 2009). There are also associations between
vitamin D deﬁciency and known risk factors for psychotic dis-
orders like urban living, winter births (Kendell and Adams, 2002)
and migration (Dealberto, 2007). Since the main negative effect of
vitamin D would be on brain development in earlier phases of life,
our ﬁndings neither support nor contradict this hypothesis.
However, the consistent ﬁndings of low S-25 OH D in visible ethnic
minorities do not contradict the need to explore the role of vita-
min D deﬁciency as one possible contributor to the higher risk of
psychosis in visible ethnic minorities.
An important strength of the current study is that the patient
sample consists of both in-and out-patients, and thus can be seen
as more representative of patients in general compared to samples
recruited from inpatients' wards only. A major limitation to the
study is the use of ethnicity as a proxy for skin pigmentation, even
if we did not ﬁnd signiﬁcant differences in S -25 OH D between
participants of Asian or African ancestry. We also lacked reliable
information about the use of vitamin D supplements or time spent
outdoors, factors that could inﬂuence S-25 OH D in all participants.
Another limitation is that two different methods for vitamin D
measurements are used in the current study. They are however
performed in the same laboratory, and the methods have been
cross-calibrated and the resulting equation has been used to ca-
librate the results to the same scale.
To conclude, participants from visible ethnic minority had
signiﬁcantly lower S-25 OH D than corresponding patient- and
control groups from the majority population and low S-25 OH D
was associated with depressive symptoms in ﬁrst episode patients.
Vitamin D deﬁciency could thus be an important factor inﬂuencing
symptom severity and co-morbidity in established psychotic dis-
order, in visible ethnic minorities already in early stages of illness.
Clinicians should routinely measure S-25 OH D in this patient
group. However, our study did not support the ﬁndings of lower
S-25 OH D in young patients diagnosed with psychotic disorders,
neither in ﬁrst episode patients nor in multi episode patients,
compared to healthy controls from the same geographical area.
This ﬁnding was not inﬂuenced by adjustments for ethnicity,
season for blood sampling, gender, age and BMI.Acknowledgments
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